You are here

Article Text

Article menu
Download PDFPDF
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
CASE REPORT
Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis
  1. Basma Abdulhadi,
  2. Ramzi Mulki,
  3. Abhinav Goyal,
  4. Janani Rangaswami
  1. Department of Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Basma Abdulhadi, abdulhab{at}einstein.edu

Summary

Non-vitamin K oral anticoagulants (NOACs) are being increasingly prescribed. These drugs act rapidly, have predictable dose-related anticoagulation effect and require no routine laboratory monitoring, making them attractive for both patients and healthcare providers. All NOACs are at least partially excreted thought the kidneys. Renal injury related to NOAC use is being increasingly reported. NOAC-related acute interstitial nephritis (AIN) has only been reported once and that was in context of dabigatran use. We describe the first case of apixaban-related AIN. This case adds an important differential diagnoses that should be considered for any patient presenting with renal injury while being treated with NOACs.

  • drugs and medicines
  • renal system
  • acute renal failure

https://doi.org/10.1136/bcr-2017-221641

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors BA contributed to conception and design, analysis of data as well as drafting the work and revising it critically for important intellectual content. RM contributed to the conception and design of the work and to the analysis and interpretation of data. AG contributed to the conception and design of the work and to the analysis and interpretation of data. JR contributed to the concept and design, critical writing and revision of the intellectual content, final approval for the version to be published.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.